In Competition Law and Policy Debate, Raphaël De Coninck highlights the European Commission’s recent interest in assessing the impact of pharmaceutical mergers on innovation. The article discusses the Commission’s approach and argues in favor of developing a consistent framework for assessing the impact of mergers on innovations. To read more, click the link below.
“Suite dreams”: Market definition and complementarity in the digital age
Certain products exhibit such strong complementarities that they should not be evaluated separately. For example, consider a pair of shoes or the various...